share_log

Yunnan Botanee Bio-Technology Group Co.LTD's (SZSE:300957) Market Cap Dropped CN¥913m Last Week; Private Companies Bore the Brunt

Yunnan Botanee Bio-Technology Group Co.LTD's (SZSE:300957) Market Cap Dropped CN¥913m Last Week; Private Companies Bore the Brunt

上周,云南博天微生物科技股份有限公司(SZSE:300957)市值下降了人民币9.13亿元;私营企业承受了主要压力。
Simply Wall St ·  07/03 21:19

Key Insights

主要见解

  • Yunnan Botanee Bio-Technology GroupLTD's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public
  • The top 2 shareholders own 61% of the company
  • 10% of Yunnan Botanee Bio-Technology GroupLTD is held by Institutions
  • 云南波特尼生物科技集团有限公司的重要私人公司所有权表明,重要决策是由更大的公众股东影响的。
  • 前两大股东占公司的股份比例为61%。
  • 10%的云南波特尼生物科技集团有限公司由机构持有。

A look at the shareholders of Yunnan Botanee Bio-Technology Group Co.LTD (SZSE:300957) can tell us which group is most powerful. With 54% stake, private companies possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

观察云南波特尼生物科技集团股份有限公司(深圳证券交易所:300957)的股东可以告诉我们哪个群体最有力量。私人公司拥有54%的股份,该集团拥有公司的最大股份数。也就是说,如果股票上涨,该集团将受益最多(或者如果出现衰退则损失最大)。

As a result, private companies as a group endured the highest losses last week after market cap fell by CN¥913m.

因此,私人公司作为一个群体,上周在市值下降91300万人民币后遭受了最大的损失。

In the chart below, we zoom in on the different ownership groups of Yunnan Botanee Bio-Technology GroupLTD.

在下面的图表中,我们放大了云南波特尼生物科技集团有限公司的不同所有权群体。

ownership-breakdown
SZSE:300957 Ownership Breakdown July 4th 2024
深圳证券交易所:300957所有权明细2024年7月4日

What Does The Institutional Ownership Tell Us About Yunnan Botanee Bio-Technology GroupLTD?

机构持股对云南波特尼生物科技集团有限公司有何影响?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

许多机构衡量其业绩的标准是一个近似于当地市场的指数。因此,他们通常更加关注包括在主要指数中的公司。

Yunnan Botanee Bio-Technology GroupLTD already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Yunnan Botanee Bio-Technology GroupLTD, (below). Of course, keep in mind that there are other factors to consider, too.

云南波特尼生物科技集团有限公司已经有机构股东了。实际上,他们在公司中拥有一个令人尊敬的股份。这意味着为这些机构工作的分析师已经看过股票,他们喜欢它。但是就像其他任何人一样,他们可能是错误的。如果两个大的机构投资者尝试同时卖出一只股票,往往会看到股价大幅下跌。因此,值得检查云南波特尼生物科技集团有限责任公司的过去盈利轨迹(参见下图)。当然,也要牢记还有其他因素要考虑。

earnings-and-revenue-growth
SZSE:300957 Earnings and Revenue Growth July 4th 2024
深圳证券交易所:300957收入和收益增长详情2024年7月4日

We note that hedge funds don't have a meaningful investment in Yunnan Botanee Bio-Technology GroupLTD. Our data shows that Kunming Nuona Technology Co., Ltd. is the largest shareholder with 46% of shares outstanding. For context, the second largest shareholder holds about 15% of the shares outstanding, followed by an ownership of 6.6% by the third-largest shareholder. In addition, we found that Zhenyu Guo, the CEO has 2.6% of the shares allocated to their name.

我们注意到,对于云南波特尼生物科技集团有限公司,对冲基金没有意义的投资。我们的数据显示,昆明诺纳技术有限公司是最大的股东,持有46%的流通股份。为了进一步了解,可以参考第二大股东持有约15%的流通股份,第三大股东持有6.6%的股份。此外,我们发现首席执行官郭振宇将2.6%的股份分配给他们的名字。

To make our study more interesting, we found that the top 2 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.

为了使我们的研究更有趣,我们发现前2名股东拥有该公司的大部分所有权,这意味着他们足够强大,可以影响公司的决策。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

研究机构所有权是衡量和过滤股票预期性能的好方法。通过研究分析师的情绪,也可以实现同样的效果。很多分析师都在关注该股票,看看他们的预测值得不值得。

Insider Ownership Of Yunnan Botanee Bio-Technology GroupLTD

云南波特尼生物科技集团有限公司内部所有权

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

虽然“内部人士”的明确定义具有主观性,但几乎所有人都认为董事会成员是内部人士。公司管理业务,但首席执行官即使是董事会成员,也要向董事会负责。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多数人认为内部所有权是积极的,因为它可以表示董事会与其他股东的利益相一致。但是,在某些场合下,这个团体的权力过于集中。

Our most recent data indicates that insiders own some shares in Yunnan Botanee Bio-Technology Group Co.LTD. This is a big company, so it is good to see this level of alignment. Insiders own CN¥512m worth of shares (at current prices). If you would like to explore the question of insider alignment, you can click here to see if insiders have been buying or selling.

我们最近的数据表明,内部人员拥有云南波特尼生物科技集团股份有限公司的一些股份。这是一个大公司,所以看到这种程度的一致性是好的。内部人员拥有现价51200万人民币的股份。如果您想探索内部人员的一致性问题,可以单击此处,查看内部人员是否一直在买入或卖出。

General Public Ownership

一般大众所有权

The general public, who are usually individual investors, hold a 18% stake in Yunnan Botanee Bio-Technology GroupLTD. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

通常为个人投资者的普通公众持有云南波特尼生物科技集团有限公司18%的股份。虽然这种所有权的规模可能不足以在他们的利益上影响政策决定,但他们仍然可以对公司的政策产生集体影响。

Private Equity Ownership

股权投资公司持有8.8%的股份,有能力参与塑造以价值创造为重点的公司策略。一些投资者可能会因此而受到鼓舞,因为股权投资公司有时可以鼓励市场看到公司的价值,从而采取有益的策略。另外,那些持有者可能在将其上市后退出投资。

Private equity firms hold a 15% stake in Yunnan Botanee Bio-Technology GroupLTD. This suggests they can be influential in key policy decisions. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

私人股权投资公司持有云南波特尼生物科技集团有限公司的15%的股份。这表明他们在关键政策决策中可能具有影响力。有时候我们会看到私人股权投资长期停留,但一般来说,他们具有更短的投资期限,并且 -- 如其名称所示 -- 并不会对公众公司进行投资。过一段时间后,他们可能会考虑出售并重新配置资金。

Private Company Ownership

私有公司的所有权

We can see that Private Companies own 54%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

我们可以看到,私营企业拥有已发行股份的54%。私营企业可能是相关方。有时内部人员通过持有私营企业的股权来投资于公共公司,而不是以个人身份。虽然很难得出任何广泛的结论,但这值得作为进一步研究的领域。

Next Steps:

下一步:

It's always worth thinking about the different groups who own shares in a company. But to understand Yunnan Botanee Bio-Technology GroupLTD better, we need to consider many other factors. Consider risks, for instance. Every company has them, and we've spotted 2 warning signs for Yunnan Botanee Bio-Technology GroupLTD you should know about.

始终考虑公司的不同股东群体是值得的。但是为了更好地了解云南波特尼生物科技集团有限公司,我们需要考虑许多其他因素。考虑风险,例如。每个公司都有风险,在我们内部发现了云南波特尼生物科技集团有限公司的2个警告标志,您应该知道。

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

如果您像我一样,可能希望考虑这家公司是否会增长或缩小。幸运的是,您可以查看此免费报告,显示分析师对其未来的预测。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

对本文有反馈?关于内容有所顾虑?直接和我们联系。或者发送电子邮件至editorial-team@simplywallst.com。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发